<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396305</url>
  </required_header>
  <id_info>
    <org_study_id>05-0070</org_study_id>
    <nct_id>NCT00396305</nct_id>
  </id_info>
  <brief_title>Th1 Response to Influenza: Aging and Vaccine Efficacy</brief_title>
  <official_title>Th1 Response to Influenza: Aging and Vaccine Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This research study is being done because influenza (flu) affects many people each year&#xD;
      throughout the world. The elderly and those with chronic health problems are at greater risk&#xD;
      for complications from the flu. The purpose of this research study is to evaluate vaccination&#xD;
      strategies in the elderly and others receiving the influenza vaccination in order to increase&#xD;
      protection. All subjects will receive the flu vaccine as an injection in the muscle of the&#xD;
      upper arm. Participants may receive a booster [an extra dose of vaccine or placebo (inactive&#xD;
      substance)] shot. Study participants will include healthy adult volunteers, ages 21-40,&#xD;
      60-89, or 90 years and older. Subjects will be involved in study related procedures for 6&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza and pneumonia are the fourth leading cause of death among people aged over 65&#xD;
      years. Influenza also leads as a cause of catastrophic disability, greatly affecting the&#xD;
      quality of life of elderly persons. In the United States alone, an estimated 10 billion&#xD;
      dollars is spent annually due to the impact of influenza, and this will rise as the&#xD;
      population of seniors rapidly expands. Thus, influenza vaccination is recommended for elderly&#xD;
      adults. Although it is cost-effective, influenza vaccination only prevents infection in 30&#xD;
      percent-40 percent of those aged over 65, compared to 70 percent-90 percent of those under&#xD;
      65. Reduced influenza vaccine efficacy and greater morbidity and mortality are thought to be&#xD;
      largely due to immune senescence, but the underlying mechanism remains poorly understood. A&#xD;
      better understanding of immune senescence can ultimately translate into improved&#xD;
      effectiveness for a variety of vaccines, including vaccines against bioterrorist attack (such&#xD;
      as small pox vaccine), and thereby bring huge advances in disease prevention and billions in&#xD;
      cost savings. The commercially available influenza vaccine used in the United States contains&#xD;
      inactivated split viral particles of influenza B and two subtypes of influenza A. These&#xD;
      vaccines are cost-effective, but far from perfect; up to 61 percent of vaccinated elderly&#xD;
      people acquire influenza infection nonetheless. The safety and cost effectiveness of the&#xD;
      licensed split influenza virus vaccine is established, reducing researchers' incentive to&#xD;
      further improve the vaccine or define the difficult and expensive-to-measure T cell-mediated&#xD;
      immunity to it. The ultimate goal of this proposed non-randomized, open-label study is to&#xD;
      improve vaccine efficacy in order to reduce morbidity and mortality from influenza and other&#xD;
      infectious diseases in elderly people. The primary objective is to examine the safety and&#xD;
      immunogenicity of vaccine strategies to enhance the Type 1 Helper Cells (Th1) response by&#xD;
      booster at the peak of Influenza specific (IS)-Th1 expansion following first vaccination. The&#xD;
      frequency of IS-Th1 and the antibody level on days 7 and 28 will be used as the two main&#xD;
      indicators of immunogenicity, although CD8+ T cell response will also be analyzed. The safety&#xD;
      profile to be assessed includes immediate adverse events, solicited local and systemic&#xD;
      events, and unsolicited adverse events. Seventy-four healthy individuals who are living&#xD;
      independently in the communities surrounding the study site will be invited to participate in&#xD;
      the trial. Participants between the ages of 21 and 40 years (young cohort) and those 60 years&#xD;
      and older (elderly cohort) will be recruited. Participants will be considered active in the&#xD;
      trial for 3 months post vaccination. A telephone follow-up visit will be scheduled at 6&#xD;
      months post-vaccination. Four groups of subjects will be recruited: 1 control group (Group 1)&#xD;
      and 3 experimental groups (Group 2, Group 3, and Group 4). This study is linked to DMID&#xD;
      protocol 05-0125. Protocol 05-0125 contains Part II of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity: measured by frequency of IS-Th1 and antibody and T cell responses.</measure>
    <time_frame>Days 7, 28, 56, and 84 following the initial vaccination.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: including rates of serious adverse events (SAEs) and their relationship to vaccination; rates of local or systemic solicited adverse events (AEs) and their categories; and reported unsolicited AEs following vaccination.</measure>
    <time_frame>Safety evaluation at 4, 14, and 28 days post-vaccination.</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 2, Control Double Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 elderly and 6 young participants. This group will be vaccinated with a double dose of vaccine without booster on Day 0. These subjects will receive a double-dose of vaccine administered as 2 consecutive injections (2 injections of 0.5 mL) in the same deltoid. The control group for Group 2 is group 1, Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3-Control late booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 21. The control for Group 3 is Group 1, Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1, Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 elderly and 8 young participants. Group 1 will be further divided into 4 equal cohorts (each containing 3 elderly and 2 young adults). Cohorts 2, 3, and 4 will receive the standard dose of vaccine and placebo (0.5 mL saline) on Day 0, 21, or 7 respectively. Cohort 1 will be vaccinated with the standard dose of vaccine without placebo/vaccine booster.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4-Control early booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 7. The control for Group 4 is Group 1, Cohort 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile phosphate buffered saline solution.</description>
    <arm_group_label>Group 1, Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent Inactivated Influenza</intervention_name>
    <description>The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.</description>
    <arm_group_label>Group 2, Control Double Dose</arm_group_label>
    <arm_group_label>Group 3-Control late booster</arm_group_label>
    <arm_group_label>Group 4-Control early booster</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females 21 to 40 years of age or between 60 and 89, or 90 years or&#xD;
             older at the time of enrollment.&#xD;
&#xD;
          -  Subjects must provide written informed consent prior to first study intervention.&#xD;
&#xD;
          -  Subject is judged to be healthy on the basis of verbal history and physical&#xD;
             examination.&#xD;
&#xD;
          -  Subject is able to cooperate with the requirements of the study (must be able to&#xD;
             complete the diary cards and will be available for 6 months after enrollment).&#xD;
&#xD;
          -  Subject is mentally capable to give consent based on investigator judgment.&#xD;
&#xD;
          -  Females of childbearing potential (all women under the age of 40) must agree to use&#xD;
             medically approved contraception and must agree to continue using this method for at&#xD;
             least three months after enrollment. Females of childbearing potential on hormonal&#xD;
             contraception must be stable on hormonal contraception and must agree to use this&#xD;
             method of contraception for at least three months after enrollment. Acceptable forms&#xD;
             of medically approved contraception include the use of: oral contraceptives,&#xD;
             injectable contraceptives (i.e., Depo-Provera), transdermal contraceptives or double&#xD;
             barrier method.&#xD;
&#xD;
          -  All females 40 years of age and under must have a negative urine pregnancy test prior&#xD;
             to any vaccination in this trial. Please note that even those participants that have a&#xD;
             history of tubal ligation or hysterectomy or are post menopausal (at least one year of&#xD;
             no menses) must still have a negative urine pregnancy test prior to any vaccination in&#xD;
             this trial.&#xD;
&#xD;
          -  Physical examination must be normal, or abnormal findings must be judged not&#xD;
             clinically significant for this patient population by the Physician Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had physician-diagnosed influenza at any time during the past two years.&#xD;
&#xD;
          -  Received an influenza vaccine 6 months preceding enrollment in the study.&#xD;
&#xD;
          -  Received any other vaccine within 30 days before starting this study or plan to&#xD;
             receive any vaccine during the 30 days after enrollment.&#xD;
&#xD;
          -  Received immunoglobulin therapy or transfusion with blood or blood products within the&#xD;
             previous three months.&#xD;
&#xD;
          -  Have known chemical dependency liable to compromise immune function (e.g., alcoholism&#xD;
             or illegal drug use not including nicotine or caffeine).&#xD;
&#xD;
          -  Are allergic to eggs or egg products, contact lens solution, or have ever had a severe&#xD;
             reaction to any vaccine.&#xD;
&#xD;
          -  Have a history of hypersensitivity (allergy) to thimerosal or formaldehyde.&#xD;
&#xD;
          -  Have chronic respiratory illnesses (clinically significant and/or on systemic&#xD;
             immunosuppressive medications e.g., asthma, COPD, emphysema).&#xD;
&#xD;
          -  Have had symptoms of an active acute respiratory or other active infections or&#xD;
             illnesses in the past 72 hours.&#xD;
&#xD;
          -  Have a temperature greater than or equal to 100.4 degrees F (38 degrees C) at&#xD;
             enrollment.&#xD;
&#xD;
          -  Known or suspected diseases of the immune system (i.e., rheumatoid arthritis, lupus&#xD;
             erythematosis, lymphoma, HIV, etc.).&#xD;
&#xD;
          -  Have active neurologic disorders (i.e., encephalopathy, optic neuritis/neuropathy,&#xD;
             partial facial paralysis, and brachial plexus neuropathy).&#xD;
&#xD;
          -  Prior history of Guillain-Barr√© Syndrome.&#xD;
&#xD;
          -  Have underlying unstable (require frequent physician office visits, have required a&#xD;
             medication change in the past 3 months and/or require frequent medication dose&#xD;
             changes) chronic disease such as cardiovascular disease (i.e., uncontrolled&#xD;
             hypertension, congestive heart failure, recent heart attack (within past 6 months),&#xD;
             cardiomyopathy; diabetes mellitus, liver disease (i.e., hepatitis, cirrhosis),&#xD;
             functional or anatomic asplenia, cancer (excluding skin and prostate cancer) or kidney&#xD;
             disease.&#xD;
&#xD;
          -  Have a history of hematologic malignancy.&#xD;
&#xD;
          -  Current treatment with an immunosuppressive medication (i.e., cancer therapeutic&#xD;
             agents, corticosteroids, excluding topical and inhaled corticosteroids).&#xD;
&#xD;
          -  Pregnant or breastfeeding females or females planning to become pregnant in the next 6&#xD;
             months.&#xD;
&#xD;
          -  Have a latex allergy.&#xD;
&#xD;
          -  Are participating in another clinical research trial within 30 days of starting this&#xD;
             trial or planning to participate in another clinical research trial at any time during&#xD;
             this trial.&#xD;
&#xD;
          -  Have any condition that would, in the opinion of the investigator, place subject at&#xD;
             risk of injury or render subject unable to meet study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>November 2, 2006</study_first_submitted>
  <study_first_submitted_qc>November 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Principal Investigator</name_title>
    <organization>Eastern Virginia Medical School</organization>
  </responsible_party>
  <keyword>Influenza, vaccine, efficacy, elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

